domperidone Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antipsychotics, risperidone derivatives 945 57808-66-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • domperidone betadex
  • domperidone betacyclodextrin
  • domperidone
  • motilium
  • peridon
  • domperidone maleate
A specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms.
  • Molecular weight: 425.92
  • Formula: C22H24ClN5O2
  • CLOGP: 4.27
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 2
  • TPSA: 67.92
  • ALOGS: -3.66
  • ROTB: 5

Drug dosage:

DoseUnitRoute
30 mg O
30 mg P
0.12 g R

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.01 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.34 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 15 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 3.40 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 9.50 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.08 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 7.50 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Jan. 1, 1982 YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Electrocardiogram QT prolonged 196.69 48.87 48 622 7766 2349649
Vomiting 129.10 48.87 60 610 71542 2285873
Akathisia 118.16 48.87 24 646 1650 2355765
Suicidal ideation 106.78 48.87 32 638 11055 2346360
Exposure during pregnancy 102.72 48.87 38 632 25181 2332234
Premature labour 101.34 48.87 22 648 2084 2355331
Nausea 92.96 48.87 56 614 112133 2245282
Gastrointestinal disorder 91.27 48.87 27 643 8890 2348525
Torsade de pointes 78.11 48.87 18 652 2228 2355187
Subileus 76.32 48.87 14 656 557 2356858
Abdominal pain 74.67 48.87 33 637 34341 2323074
Urinary retention 74.22 48.87 19 651 3648 2353767
Dehydration 70.52 48.87 28 642 22267 2335148
Pyrexia 69.21 48.87 36 634 53672 2303743
Coma 65.37 48.87 21 649 9035 2348380
Vascular encephalopathy 62.40 48.87 9 661 74 2357341
Hyperprolactinaemia 60.74 48.87 12 658 710 2356705
Psychotic disorder 60.40 48.87 17 653 4662 2352753
Parkinson's disease 58.97 48.87 13 657 1313 2356102
Somnolence 58.91 48.87 25 645 23460 2333955
Fatigue 58.82 48.87 38 632 84835 2272580
Faecaloma 57.90 48.87 12 658 903 2356512
Condition aggravated 57.66 48.87 27 643 31952 2325463
Dystonia 57.53 48.87 14 656 2180 2355235
Rash maculo-papular 57.39 48.87 16 654 4236 2353179
Mydriasis 57.38 48.87 14 656 2205 2355210
Intentional overdose 56.91 48.87 20 650 11301 2346114
Respiratory depth decreased 56.72 48.87 7 663 13 2357402
Dementia 54.75 48.87 14 656 2667 2354748
Diarrhoea 54.40 48.87 36 634 83528 2273887
Hypokalaemia 54.22 48.87 19 651 10635 2346780
Hyponatraemia 53.72 48.87 20 650 13305 2344110
Duodenal stenosis 52.79 48.87 8 662 95 2357320
Dizziness 52.58 48.87 31 639 58634 2298781
Pituitary tumour benign 50.07 48.87 9 661 318 2357097
Infusion site vesicles 49.27 48.87 7 663 51 2357364

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hepatocellular injury 51.50 37.01 13 287 3218 1743263
Lactic acidosis 45.54 37.01 13 287 5116 1741365
Pericardial effusion 41.19 37.01 11 289 3379 1743102
Intentional overdose 40.38 37.01 13 287 7657 1738824
Vomiting 39.53 37.01 20 280 38295 1708186

Pharmacologic Action:

SourceCodeDescription
ATC A03FA03 ALIMENTARY TRACT AND METABOLISM
DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS
PROPULSIVES
Propulsives
MeSH PA D000932 Antiemetics
MeSH PA D002491 Central Nervous System Agents
MeSH PA D015259 Dopamine Agents
MeSH PA D018492 Dopamine Antagonists
MeSH PA D005765 Gastrointestinal Agents
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018373 Peripheral Nervous System Agents
CHEBI has role CHEBI:50919 antiemetic
CHEBI has role CHEBI:48561 dopaminergic antagonist

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Nausea and vomiting indication 16932000
Acute gastric ulcer with perforation contraindication 19850005
Torsades de pointes contraindication 31722008
Acute nephropathy contraindication 58574008
Acute gastric ulcer with hemorrhage contraindication 89748001
Prolonged QT interval contraindication 111975006
Gastrointestinal obstruction contraindication 126765001
Disease of liver contraindication 235856003 DOID:409
Pregnancy, function contraindication 289908002
Congenital long QT syndrome contraindication 442917000
Pituitary Prolactinoma contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.45 acidic
pKa2 10.04 acidic
pKa3 7.79 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
D(2) dopamine receptor GPCR ANTAGONIST Ki 8.40 IUPHAR IUPHAR
Mu-type opioid receptor GPCR Ki 5.77 DRUG MATRIX
Alpha-2A adrenergic receptor GPCR Ki 5.99 DRUG MATRIX
Sodium-dependent serotonin transporter Transporter Ki 5.79 DRUG MATRIX
Sodium-dependent noradrenaline transporter Transporter Ki 5.59 DRUG MATRIX
5-hydroxytryptamine receptor 2A GPCR Ki 7.96 DRUG MATRIX
5-hydroxytryptamine receptor 2B GPCR Ki 5.78 DRUG MATRIX
5-hydroxytryptamine receptor 2C GPCR Ki 6.16 DRUG MATRIX
Alpha-2B adrenergic receptor GPCR Ki 6.01 DRUG MATRIX
Histamine H1 receptor GPCR Ki 6.81 DRUG MATRIX
Alpha-2C adrenergic receptor GPCR Ki 6.83 DRUG MATRIX
Alpha-1D adrenergic receptor GPCR Ki 6.94 DRUG MATRIX
Kappa-type opioid receptor GPCR Ki 5.55 DRUG MATRIX
Calmodulin Cytosolic other WOMBAT-PK
Alpha-1B adrenergic receptor GPCR Ki 6.28 WOMBAT-PK
Cytochrome P450 2D6 Enzyme Ki 5.10 WOMBAT-PK
Aldehyde oxidase Enzyme IC50 5.52 WOMBAT-PK
Alpha-1A adrenergic receptor GPCR Ki 6.65 WOMBAT-PK
Potassium voltage-gated channel subfamily H member 2 Ion channel IC50 6.79 WOMBAT-PK
Solute carrier family 22 member 2 Transporter IC50 5.10 CHEMBL
D(3) dopamine receptor GPCR Ki 8.46 CHEMBL
Multidrug and toxin extrusion protein 2 Transporter IC50 4.83 CHEMBL
Multidrug and toxin extrusion protein 1 Transporter IC50 5.64 CHEMBL
Multidrug resistance protein 1 Transporter WOMBAT-PK
Alpha-1B adrenergic receptor GPCR Ki 7.06 DRUG MATRIX
D(3) dopamine receptor GPCR Ki 7.93 CHEMBL
D(2) dopamine receptor GPCR Ki 9.28 CHEMBL
Alpha-1A adrenergic receptor GPCR IC50 6.55 CHEMBL

External reference:

IDSource
D004294 MESH_DESCRIPTOR_UI
4025225 VUID
N0000171760 NUI
C0013015 UMLSCUI
D01745 KEGG_DRUG
5587267Z69 UNII
4110 INN_ID
32955006 SNOMEDCT_US
3626 RXNORM
387181004 SNOMEDCT_US
4025225 VANDF
003454 NDDF
83898-65-1 SECONDARY_CAS_RN
CHEMBL219916 ChEMBL_ID
DB01184 DRUGBANK_ID
CHEBI:31515 CHEBI
965 IUPHAR_LIGAND_ID
3151 PUBCHEM_CID

Pharmaceutical products:

None